Hypoxic-ischemic related cerebrovascular changes and potential therapeutic strategies in the neonatal brain

Clémence DISDIER1, Barbara S STONESTREET1,*

1Department of Pediatrics, Women & Infants Hospital of Rhode Island, The Alpert Medical School of Brown University, Providence, RI 02905, USA

Abstract

Perinatal hypoxic-ischemic (HI)-related brain injury is an important cause of morbidity and long-standing disability in newborns. The only currently approved therapeutic strategy available to reduce brain injury in the newborn is hypothermia. Therapeutic hypothermia can only be used to treat HI encephalopathy in full term infants and survivors remain at high risk for a wide spectrum of neurodevelopmental abnormalities as a result of residual brain injury. Therefore, there is an urgent need for adjunctive therapeutic strategies. Inflammation and neurovascular damage are important factors that contribute to the pathophysiology of HI-related brain injury and represent exciting potential targets for therapeutic intervention. In this review, we address the role of each component of the neurovascular unit (NVU) in the pathophysiology of HI-related injury in the neonatal brain. Disruption of the blood-brain barrier (BBB) observed in the early hours after an HI-related event is associated with a response at the basal lamina level, which comprises astrocytes, pericytes, and immune cells, all of which could affect BBB function to further exacerbate parenchymal injury. Future research is required to determine potential drugs that could prevent or attenuate neurovascular damage and/or augment repair. However, some studies have reported beneficial effects of hypothermia, erythropoietin, stem cell therapy, anti-cytokine therapy and metformin in ameliorating several different facets of damage to the NVU after HI-related brain injury in the perinatal period.

Keywords

neurovascular unit; hypoxia ischemia; brain injury; neonates

Elements of the illustrations were provided by Servier Medical Art by Servier (http://smart.servier.com) licensed under a Creative Commons Attribution 3.0 Unported license. Some of the elements were adapted.

*Author to whom correspondence should be addressed. Correspondence: Barbara S Stonestreet, MD, The Alpert Medical School of Brown University, Department of Pediatrics, Women & Infants Hospital of Rhode Island, 101 Dudley Street, Providence, RI 02905, Phone: (401) 274-1122, x 47429, bstonestreet@wihri.org.

AUTHOR CONTRIBUTIONS
Both authors take responsibility for the integrity and accuracy of this review. Conceptualization, C.D and B.S.S.; Writing – Original Draft, C.D.; Writing – Review & Editing, C.D. and B.S.S.; Funding Acquisition, B.S.S.

CONFLICT OF INTEREST
There are no conflicts of interest to report.
1 | Introduction

The Blood-Brain barrier (BBB) is an important contributor to the maintenance of central nervous system (CNS) homeostasis that prevents the entry of many detrimental substances into the nervous tissue. The brain endothelial cells (BECs) of the BBB supply nutrients and other essential molecules from blood to brain cells and eliminate waste products to provide an optimal environment for brain development. The BECs are also important for signal transduction including numerous immune responses. For example, immune blood born cell trafficking is regulated in part by the expression of adhesion molecules on BECs. It is important to emphasize that BECs by themselves are not capable of intrinsically forming a fully functional BBB. The relatively new concept of neurovascular unit (NVU) underscores the requirement for coordinated cell interactions that include BECs, the basal lamina, the surrounding glial limitans, pericytes, microglia and neurons (Hawkins & Davis, 2005; Iadecola, 2017). The function of this unique barrier requires interactions and coordination among the multiple cellular constituents and the extracellular matrix (ECM) to establish an effective anatomical and functional barrier system.

BECs possess the most characteristic features of the barrier in the brain, which include reduced paracellular transport as a result of tight junctions (TJ) between neighboring BECs and the expression of efflux and influx transporters that regulate the brain microenvironment (Ek, Dziegielewska, Habgood, & Saunders, 2012; Saunders, Liddelow, & Dziegielewska, 2012; Strazielle & Ghersi-Egea, 2015; Virgintino et al., 2000). TJs are present and functional early in brain development both in laboratory animals (Bauer et al., 1993; Daneman, Zhou, Agalli, et al., 2010; Ek, Dziegielewska, Stolp, & Saunders, 2006; Ek, Habgood, Dziegielewska, & Saunders, 2003; Hirase et al., 1997; Kniesel, Risau, & Wolburg, 1996) and in human fetuses (Anstrom, Thore, Moody, & Brown, 2007; Ballabh, Hu, Kumarasiri, Braun, & Nedergaard, 2005; Virgintino et al., 2004). The vascular basal lamina components appear associated with detectable occludin and claudin-5 in the primary cerebral cortical vessels by 12 weeks of the human gestation (Anstrom et al., 2007; Ballabh et al., 2005; Virgintino et al., 2004; Virgintino et al., 2007). Claudins and occludin reorganize to concentrate in linear discontinuous tracts to form immature TJ strands between week 12 and 14 weeks of the human gestation (Virgintino et al., 2004). TJ proteins display the adult like appearances at the junctional area between endothelial cells a few weeks later. The physical barrier mechanism(s) established early in development facilitate a stable environment needed for brain maturation. On the other hand, the ontogeny of transporters at the BBB show that the expression of some carriers differ between the neonatal and the adult brain (Ek, D’Angelo, Lehner, et al., 2015; Ek et al., 2012; Ek et al., 2010; Harati, Benech, Villegier, & Mabondzo, 2013; Lam et al., 2015; Mollgard, Dziegielewska, Holst, Habgood, & Saunders, 2017; Soares, Do, Mabondzo, Pons, & Chhun, 2016). The developmental expression shows different profiles depending on transporters in both humans and animals. The NVU is also a metabolic barrier because BECs and other NVU cells express metabolic enzymes for neurotransmitters and cytochromes P450 (Decleves et al., 2011; Shawahna et al., 2011). The ontogeny of all these systems has not yet been fully delineated in the developing brain. Developmental changes in the expression of pumps, transporters and
metabolic enzymes may reflect specific requirements of a developing brain and, therefore, the effects of injury during development could differ from those in the adult brain.

A number of brain related injuries observed in neonates could also be caused by genetic-related and other factors that occur during antenatal brain development (MacLennan, Thompson, & Gecz, 2015). Sometimes the etiological basis of adverse neurological and behavioral symptoms cannot be determined by the clinical events occurring during the perinatal period. Despite these factors and in contrast to the “mechanistic” approach provided by MacLennan et al., other etiologies of neonatal brain injury potentially include perinatal stroke, intraventricular hemorrhage and asphyxia with hypoxia/ischemia, which could have similar pathways predisposing to injury (Hagberg et al., 2015). The main molecular pathways activated by the simultaneous actions of HI and genetic abnormalities could be associated with the subsequent HI-related perinatal brain injury. However, these factors remain controversial because the protective effects of mild anoxia/hypoxia have also been demonstrated in animal models of perinatal brain injury (Alotaibi, Arrowsmith, & Wray, 2015).

Normal brain development is highly dependent on a sufficient blood, oxygen and energy supply. HI-related brain injury is a result of an insufficient blood flow to the brain combined with lower-than-normal concentrations of oxygen in the arterial blood. These events in the immature and developing brain cause significant mortality and can result in long-term neurological deficits such as cerebral palsy, epilepsy and seizure disorders, developmental delay, severe learning disabilities, cognitive, motor and behavioral abnormalities (Conklin, Salorio, & Slomine, 2008; Fatemi, Wilson, & Johnston, 2009; Kharoshankaya et al., 2016; Pappas et al., 2015). Randomized controlled trials of therapeutic hypothermia in full term infants have demonstrated a decrease in death or severe disability 18 months after the insult. However, death and disabilities continue to occur in 30 to 70% of infants regardless of treatment with therapeutic hypothermia (Azzopardi et al., 2010; Shankaran et al., 2005; Tagin, Woolcott, Vincer, Whyte, & Stinson, 2012). After the relative success of translating therapeutic hypothermia from the bench to the bedside for neuroprotection, adjunctive treatments to further enhance the neuroprotective efficacy of hypothermia have recently been extensively investigated. HI-related brain injury is characterized by a pronounced neurovascular inflammatory response (Back, 2006; Bartha et al., 2004; Hagberg et al., 2015; Liu & McCullough, 2013) along with early structural vasculature alterations (Moretti et al., 2015). Both inflammation and BBB abnormalities can contribute to neuronal damage. Therefore, neurovascular inflammation and vasculature structural alterations represent basic mechanisms in HI-related brain injury and, consequently, potential therapeutic targets. Elucidating the mechanisms underlying the responses of the NVU to HI in the neonatal brain is critical because they could give insights into potential endogenous neuroprotective pathways that could suggest therapeutic targets. The purpose of this review is to summarize the current knowledge regarding effects of HI-related injury to the NVU in the neonatal brain. In addition, we also summarize the effects of several therapeutic interventions such as erythropoietin or stem cell therapy, which are the only therapies that have been examined with reference to changes in the NVU.
2 | The neonatal neurovascular unit in hypoxic ischemic conditions

2.1 | From HI animal models to human NVU

Animal models used for the study of HI-related brain injury in neonates have been reviewed in detail by others (Ashwal & Pearce, 2001; Hagberg, Ichord, Palmer, Yager, & Vannucci, 2002; Koehler, Yang, Lee, & Martin, 2018; Millar, Shi, Hoerder-Suabedissen, & Molnar, 2017; Rumajogee, Bregman, Miller, Yager, & Fehlings, 2016). These reviews have addressed interspecies differences as well as the appropriateness of various animal models including rodents to study HI-related brain injury. The characteristics of brain development have been established in several species to support the use of appropriate animal models to study neonatal brain injury (Clancy, Darlington, & Finlay, 2001; Clancy, Finlay, Darlington, & Arland, 2007; Dobbing & Sands, 1979). The most widely used model of HI-related brain injury is the Rice-Vannucci model, which combines unilateral carotid artery ligation with exposure to variable lengths of hypoxia in 7-day-old rat pups (Rice, Vannucci, & Brierley, 1981).

There is now sufficient evidence to justify the use of 7-days old rats because the brain maturation is thought to be roughly comparable to that of the third trimester human fetus (Clancy et al., 2001). Nonetheless, various species have been categorized into prenatal, perinatal and postnatal brain developers with reference to their brain growth velocity relative to the time of birth (Dobbing & Sands, 1979). In this regard, the human and pig exhibits mainly perinatal brain growth, whereas the rodent brain matures after birth (Dobbing & Sands, 1979). Studies have revealed that the structure of the NVU exists and is relatively similar among a variety of species including rodents and large animals such as the piglet and lamb that have been used to study HI-related brain injury (O’Brien, Pfau, & Gu, 2018). The structure of the NVU in the human brain appears to be like that of other mammals. However, the NVU in the human brain exhibits several unique features including a greater number of astrocytes with a more elaborate astrocytic network than observed in the rodent brain (Oberheim, Wang, Goldman, & Nedergaard, 2006). The species differences in the features of the NVU have not been investigated in the developing brain with reference to the complex molecular interactions among the cellular elements (brain endothelial cells, astrocytes, pericytes, inflammatory cells, and neurons) and the acellular (basal lamina) components of the NVU that cooperatively contribute to BBB integrity. Therefore, the translation of observations from HI-related brain injury in animal models to the developing human neonate needs to be considered with caution.

2.2 | Endothelial cells

BECs represent the fundamental cell type of the BBB because they are the first cells to encounter substances in the systemic circulation. The BECs differ considerably from classic endothelial cells in peripheral vessels because they contain a large quantity of cytosolic mitochondria, low pinocytotic activity and lack fenestrations. The tight junctions (TJ) between neighboring cells form the physical barrier separating blood stream and brain parenchyma and resulting in very limited paracellular passage. Various transport systems are present on abluminal and luminal membranes also regulate the transcellular traffic. These polarized transporters are responsible for the selective ‘transport barrier’ in order to meet the
high nutritional and energy requirements of the brain and to exclude potentially harmful substances such as exogenous toxins circulating in blood.

2.2.1 | HI related changes in permeability—Disturbances in endothelial permeability have been evaluated by several methods and described in multiple models of HI-related injury in the fetal and neonatal brain (Table 1). Many of these studies were performed using the Rice-Vannucci model in rodents and describe extravagation of blood born molecules such as albumin or IgG within a few hours after the insult. Some studies also reported increases in permeability to small injected molecules such as sucrose, dextran or fluorescein. Normalization in barrier function has been observed to range from 3 to 7 days after barrier opening resulting from HI-related events. The differences observed in the time of recovery may be a result of differences in the models used and the extent of brain injury. The effects of ischemic-reperfusion related brain injury and umbilical cord occlusion on BBB function has been examined in fetal sheep. Several studies have demonstrated similar increases in BBB permeability. In summary, there is agreement that the HI and/or ischemic injury in the neonatal or fetal brain induce an increase in BBB permeability.

Findings in human neonates appear to be consistent with these observations because albumin concentrations in cerebro-spinal fluid compared with plasma levels are increased in infants that had been exposed to hypoxic-ischemic encephalopathy (HIE) (Aly et al., 2009; Kumar, Mittal, Khanna, & Basu, 2008). The impaired supply of oxygen and glucose after HI-related injury results in an anaerobic stress and initiates a cascade of ATP depletion, efflux of excitotoxic glutamate, ion shifts, and metabolic imbalances associated with acidosis, oxidative stress, and release of pro-inflammatory cytokines. These stress induced signals can directly affect BBB permeability, predispose to cerebral edema and promote entry of neurotoxic substances into the brain parenchyma (N. Joan Abbott & Friedman, 2012; Stanimirovic & Satoh, 2000). Endothelial activation and increases in BBB permeability contribute to HI-related brain injury by intensifying the exposure to pro-inflammatory mediators in the systemic circulation and by initiation and further propagation of the inflammatory waves across the brain parenchyma. Mechanisms underlying these changes have largely been described in the adult brain (Kaur & Ling, 2008; Yang, Hawkins, Dore, & Candelario-Jalil).

The tightness of the BBB endothelium is a result of TJ proteins that seal neighboring BECs and restrict the diffusion from the lumen of the vessel into the brain parenchyma. The TJs are composed of a combination of transmembrane (claudins family and occludin) and cytoplasmic (i.e. zonula occludens (ZO) family) proteins that interact with the actin cytoskeleton. Decreases in the expression of TJ proteins have been reported after HI-related injury in the rodent brain (W. Q. Chen et al., 2009; Ek, D’Angelo, Baburamani, et al., 2015; Fang et al., 2017; Ma, Dasgupta, Li, Huang, & Zhang, 2017; W. T. Zhang et al., 2016) and after ischemia-reperfusion in the brain of fetal sheep (Malaeb, Sadowska, & Stonestreet, 2007; Sadowska et al., 2012) in association with increases BBB permeability. The ontogeny of TJs and the measure of BBB integrity in the developing brain demonstrated that the barrier is fully functional from early in CNS development (Daneman, Zhou, Agalliu, et al., 2010; Ek et al., 2006; Ek et al., 2003), therefore, it is not surprising that effect of HI on alterations permeability are somewhat similar between the adult and neonatal brain.
vasculature. However, whether the neonatal BBB can recover after this initial increase of permeability remains to be determined. Alterations in BBB permeability are often observed in epilepsy long after an exposure to HI-related brain injury (Bankstahl et al., 2018; Marchi, Granata, Ghosh, & Janigro, 2012; van Vliet et al., 2007). Thus, further investigation is required to fully understand the recovery of the barrier properties and long-term consequences to the immature brain. The developmental status of the cerebral vasculature could be a critical contributing factor to the pathogenesis of HI-related brain injury. Muramatsu et al. showed that the BBB of younger rat (P7) was more vulnerable to HI damage compared with older rats (P21) (Muramatsu, Fukuda, Togari, Wada, & Nishino, 1997). Moreover, most of the studies summarized above studied BBB function in animal models that simulated the cerebral development similar to the brain of full-term human infant. Studies have not yet evaluated the effects of HI insults on BBB permeability in animal models that are similar to the premature human brain.

In addition, there is increasing evidence of sexual dimorphism in response to neonatal HI-related injury that remains to be explained (Charriaut-Marlangue, Besson, & Baud, 2018). Immune related modifications in the BBB have been shown to be sex-dependent in the adult (Erickson et al., 2018). However, the sex related differences in BBB permeability has not been examined in the neonatal brain.

2.2.2 | Transport system dysfunction—The transport systems at the BBB have two main purposes: To carry essential molecules (nutrients, amino acids, etc.) and to limit the entry of xenobiotics into the brain via the efflux system. In this regard, the ATP binding cassette (ABC) transporters P-glycoprotein (Pgp) (Lam et al., 2015), Breast Cancer Resistance Protein (BCRP) (Eisenblatter, Huwel, & Galla, 2003), Multidrug Resistance-associated Proteins (MRPs) MRP4 and MRP5 (Seetharaman, Barrand, Maskell, & Schepfer, 1998), and OATP1A2 and OATP2B1 along with the Organic Anion Transporting Polypeptides (OATPs) (Roth, Obaidat, & Hagenbuch, 2012) are considered the most clinically significant transporters within the BECs. The ontogeny of transporters at the BBB show that the expression of some carriers differ between the neonatal and adult brain (Ek, D’Angelo, Lehner, et al., 2015; Ek et al., 2012; Ek et al., 2010; Harati et al., 2013; Lam et al., 2015; Mollgard et al., 2017; Soares et al., 2016; Strazielle & Ghersi-Egea, 2015; Tsai et al., 2002). The activity of transporters at the molecular level can be modulated by a numerous physiological signals such as activation of intracellular protein kinases and transcription factors (Miller, 2015). HI results in the release of an array of complex signaling molecules that can enhance these signaling pathways including, reactive oxygen species, pro-inflammatory cytokines and chemokines.

Radiolabeled interleukin-1 β (IL-1 β) transfer across the BBB has been shown to be increased at 4 h and 24 h after exposure to ischemic brain injury in fetal sheep in utero (Patra et al., 2017; Sadowska et al., 2012). The increases in IL-1 β transfer were most likely explained by changes in the activity and/or expression of a specific IL-1 transporter at the BBB. Consistent with this finding, previous work has shown that there is a proportionately greater propensity for cytokines to cross the BBB despite their large size as a result of saturable transport systems (William A. Banks, 2010; W. A. Banks, Kastin, & Broadwell, 1995; Threlkeld et al., 2010). Even though the specific carrier for IL-1 β has not been
identified yet, these observations suggest that HI could trigger neurovascular inflammatory responses that could modify BBB transport systems.

Glucose, an essential substrate for brain oxidative metabolism, is transported across the BBB into glia and neurons by a family of structurally related membrane spanning glycoproteins called facilitative glucose transporters (glut) (Vannucci & Vannucci, 2000). Glucose transporters belong to the solute carrier (SLC) transporter family. Fung et al demonstrated that brain injury was augmented in glut 3 deficient mice after exposure to an HI insult (Fung et al., 2010). This study emphasizes the importance of the glut 3 transporter in neonatal HI-related brain injury. However, modifications in the activity and/or expression of transporters critical to the supply of metabolic substrates have not been investigated in wild-type rodents after HI-related injury in the neonatal brain.

The expression of major efflux and influx pumps, such as the ABC or SLC transporters, have not been investigated in the neonatal brain after HI injury, even though they have a major role in BBB function. However, studies in adults suggest that ischemic stroke can modify BBB transporter function. For example, P-glycoprotein (P-gp/MDR1/ABCB1), a particularly important ABC transporter that is responsible for handling a wide variety of endogenous substrates and xenobiotics, is upregulated after ischemic stroke in rodents (Cen et al., 2013; Cui et al., 2015; Spudich et al., 2006). The breast cancer resistant protein (BCRP/ABCG2) expression is also increased in the peri-infarct areas (Dazert et al., 2006; Shin et al., 2018).

In summary, there is a paucity of information regarding the regulation of transport activity across the BBB after HI-related injury in the neonatal brain. It is likely that there is an age dependent response of the transporters to HI in the neonatal brain because ontogenic modulations in transporters have been reported at the BBB during development. Transporters (i.e. ABC and SLC) provide a considerable opportunity to protect the BBB and/or promote BBB repair by facilitating endothelial uptake of drugs with cytoprotective/antioxidant properties or by preventing cellular loss of critical endogenous substances. However, further work is required to provide information regarding the interplay of cell-to-cell interactions, transporters, and signaling pathways at the BBB endothelium to understand how these systems could be effectively targeted. Furthermore, these systems are extremely important and require further investigation because infants with HIE are currently exposed to numerous medications for which these transporters could have important effects on brain drug concentrations and deposition.

2.2.3 | Metabolism—BECs express several enzymes responsible for the metabolism of neurotransmitters. For example, they express monoamine esterases, cholinesterases, GABA transaminases, aminopeptidases and endopeptidases. BECs also express different systems responsible for the metabolism of drugs typically found in the liver, such as the cytochromes P450 (CYP450 or phase I enzymes) and phase II enzymes of metabolism (Daneman, Zhou, Agalliu, et al., 2010; Decleves et al., 2011; Munji et al., 2019; Shawahna et al., 2011). Toxin and drug-metabolizing enzymes contribute along with the efflux transporters to detoxification at the BBB (El-Bacha & Minn, 1999). In addition, enzymes are important to metabolize endogenous substrates such as fatty acids, hormones, steroids, and vitamins and
regulate the concentration of signaling pathway molecules. The ontogeny of the different enzyme systems has not been examined in the developing brain or with respect to their regulation after injury. The effects of HI-related injury on metabolic enzymes and their regulation at the BBB have been investigated even in the adult brain.

HI-related brain damage is mediated through numerous overlapping mechanisms resulting in cell death: excitotoxicity, oxidative stress and inflammation (Back, 2015; Back & Miller, 2014; Ferriero, 2004; Gonzalez & Ferriero, 2008; Jantzie et al., 2015; Northington, Graham, & Martin, 2005). The mechanisms underlying the vulnerability of the immature brain to cell death remain controversial (Northington, Chavez-Valdez, & Martin, 2011; Northington et al., 2005). This sensitivity might be partly explained by the higher expression of the N-methyl-D-aspartate (NMDA) receptor in the developing brain compared to the adult. The NMDA receptor is an ionotropic glutamate receptor stimulated during excitotoxicity that is expressed at 150–200 percent higher amounts in P6 rats compared with those in adults (Tremblay, Roisin, Represa, Charriautmarlangue, & Benari, 1988). Apoptosis, necroptosis/necrosis as well as autophagic cell death are mechanisms described after HI-related brain injury in the immature brain. However, studies have not examined the specific sensitivity of the endothelium to cell death in context of HI-related brain injury in the neonatal brain.

2.2.4 | The extracellular matrix, angiogenesis and neovascularization—The basal lamina membrane is composed of ECM proteins (collagen sub-units, heparin sulfate proteoglycans, laminin, fibronectin, etc.) (Ballabh, Braun, & Nedergaard, 2004; Hawkins & Davis, 2005; Zlokovic, 2008). BECs and pericytes, as described in detail below, are in direct contact with the basal lamina.

ECM glycoprotein staining can be used to examine vasculature density after HI injury in the neonatal brain. Laminin was used as maker to show decreased vessel density after umbilical cord occlusion fetal sheep. Decreases in vessel density was observed in the caudate nucleus along with shifts in the frequency of smaller to larger blood vessels in periventricular and subcortical white matter. In contrast, blood vessel density and morphology did not change after ischemia in the cerebral cortex (Baburamani, Lo, Castillo-Melendez, & Walker, 2013). Blood vessel density also decreased after HI-related injury in rodents (Hsu et al., 2014) and newborn piglets (Jain, Kratimenos, Koutroulis, Buddhavarapu, & Ara, 2017). Several studies have suggested that angiogenesis promotes neovascularization within several days after ischemic brain injury in neonatal rodents. These findings are based on results from a variety of models including neonatal stroke (D. Z. Mu et al., 2003) and prolonged hypoxia (Ogunshola et al., 2000). Morphometric analysis of cerebral cortical microvessels showed that neovascularization began at approximately 72 h after transient carotid occlusion in fetal sheep (Virgintino et al., 2014).

Vascular endothelial growth factor (VEGF) is a key mediator of vessel proliferation that is up regulated after neonatal HI. VEGF signaling pathways have been shown to stimulate angiogenesis after recovery from HI-related brain injury in neonatal rodents (Lyons, Anderson, & Meyer, 1991; Shimotake, Derugin, Wendland, Vexler, & Ferriero, 2010; Tang et al., 2017). Significant increases in the percentage of VEGF expressing blood vessels were observed in the subventricular zone and in periventricular and subcortical white matter 24
and 48 hours after umbilical cord occlusion in the ovine fetus (Baburamani, Castillo-Melendez, & Walker, 2013). Although VEGF up-regulation in support of neovascularization is potentially neuroprotective, the up-regulation also increases BBB permeability resulting in subsequent leakage of blood-born substances into the brain parenchyma and predisposition to brain edema (Baburamani, Ek, Walker, & Castillo-Melendez, 2012).

Basic fibroblast growth factor (FGF-2) and hypoxia-inducible factor-1α (HIF-1α) are two other growth factors that have been shown to augment angiogenesis after FI I in neonatal rodents (Lu, Jiang, Zhu, Zhang, & Wang, 2014; Lyons et al., 1991; D. Z. Mu et al., 2003; Tang et al., 2017). HIF-1α is a nuclear factor that modulates many HI-related processes including neovascularization by regulating the transcription of its downstream elements such as VEGF. Increases in cerebral cortical FGF-2 was also associated with increases in neovascularization in the ovine cerebral cortex after ischemia (Virgintino et al., 2014).

Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases. They are responsible for remodeling the extracellular matrix including the basal lamina of the BBB, regulating cell receptors and cleaving their ligand binding domains in the brain (Bonnans, Chou, & Werb, 2014; Kim, Turnbull, & Guimond, 2011; Nagase, Visse, & Murphy, 2006; Visse & Nagase, 2003). Tissue injury and inflammatory responses after HI insults can result in matrix degradation and predispose to disruption of the BBB. MMPs are mainly released from activated microglia and infiltrating leukocytes but they are also highly expressed in BECs and astrocyte end-feet processes. There is now substantial information demonstrating that degradation of basement membrane proteins by several MMPs that are elevated after ischemia and HI in the fetal and neonatal brain (W. Q. Chen et al., 2009; X. Chen, Patra, Sadowska, & Stonestreet, 2018; Leonardo et al., 2008; Ranasinghe et al., 2009; Savard et al., 2015; Svedin, Hagberg, Savman, Zhu, & Mallard, 2007; W. T. Zhang et al., 2016). Pro-inflammatory cytokines stimulate the proteolytic activity of MMPs. However, MMPs also enhance inflammatory responses by cleavage of pro-inflammatory cytokines attached to cell surfaces releasing these molecules into the extracellular milieu (Gearing et al., 1995; Schonbeck, Mach, & Libby, 1998).

### 2.3 Pericytes

Pericytes surround the BBB providing additional separation of the blood components from neural tissue. They are evenly spaced along the walls of capillaries and share a common basal lamina with BECs. Pericytes are also termed vascular smooth muscle cells or myofibroblasts of blood vessels because of their ability to contract and, consequently, regulate local microvascular blood flow (Bandopadhyay et al., 2001; Cardoso, Brites, & Brito, 2010). They also have a critical role in cellular communication within the NVU. Gap junctions enable direct exchange of ions and small molecules between pericytes and BECs. In addition, they preserve the structure of the BBB by stimulating TJ formation (Ballabh et al., 2004; Daneman, Zhou, Kebede, & Barres, 2010; Dente, Steffes, Speyer, & Tyburski, 2001; Nakagawa et al., 2007). They also have a critical role in the development, maturation, remodeling of blood vessels (Paula Dore-Duffy & Cleary, 2011; Hirschi & Damore, 1996) and in inflammatory processes (Dalkara, Gursoy-Ozdemir, & Yemisci, 2011; Hawkins & Davis, 2005).

*J Neurosci Res. Author manuscript; available in PMC 2021 January 01.*
There is a paucity of information regarding the role of pericytes after HI in the neonatal brain. Most of the information regarding the response of pericytes to HI has been reported in the adult brain. Pericytes migrate away from microvessels after HI in the adult brain (P. Dore-Duffy et al., 2000; Duz, Oztas, Erginay, Erdogan, & Gonul, 2007; Fernandez-Klett et al., 2013; Gonul et al., 2002; Hall et al., 2014). Perivascular cells are not the first cells to respond to HI-related brain injury and are less sensitive than BECs to HI injury (Engelhardt, Huang, Patkar, Gassmann, & Ogunshola, 2015). They also regulate cellular interactions at the NVU and TJ protein localization in BECs in vitro during exposure to hypoxia (Al Ahmad, Taboada, Gassmann, & Ogunshola, 2011). Likewise, they reduce apoptosis in BECs thereby stabilizing the endothelium (Ramsauer, Krause, & Dermietzel, 2002). However, the potential beneficial effects of pericytes to preserve the structural integrity of the barrier remain to be examined in vivo. Several other observations also support concept that pericytes stimulate angiogenesis by synthesizing growth factors and components of the basal lamina (Paula Dore-Duffy, 2008; Paula Dore-Duffy & Cleary, 2011; Hirsch & Damore, 1996). Consequently, pericytes may be key regulators of repair after HI-related brain injury in the neonatal brain and offer an opportunity as a potential therapeutic target.

2.4 | Astrocytes

Astrocytes are the most abundant class of cells in the NVU (N. J. Abbott, 2002). They cover BECs and pericytes, and approximately 98% of the cerebral vascular surface area with their extensions termed astrocytic end foot processes (Mathiesen, Lehre, Danbolt, & Ottersen, 2010). Their unique form allows them to create an interface between BECs and neurons. Consequently, they provide nutritive support for neurons and regulate endothelia vascular permeability. Therefore, pericytes and astrocytes contribute to the establishment of the specialized phenotype of the BBB (Kimelberg & Nedergaard, 2010). This theory is supported by numerous in vitro studies demonstrating that co-cultures of BECs with astrocytes generate much tighter barrier properties than BECs cultures without astrocytes (Helms et al., 2016).

HI injury in the neonatal brain is associated with extensive astrogliosis (Chavez-Valdez, Martin, Flock, & Northington, 2012; C. Y. Chen et al., 2015; Huang et al., 2017; Qiu et al., 2007; Sullivan, Bjorkman, Miller, Colditz, & Pow, 2010; Teo, Morris, & Jones, 2015; Virgintino et al., 2014). Astrocytes exhibit morphologic changes (hypertrophy with swelling of end-feet) immediately after exposure to a HI-related insult. They proliferate and glial fibrillary acidic protein (GFAP) expression increases resulting in the formation of glial scars in the damaged area associated with HI. The role of reactive astrogliosis remains unclear, but most likely has a dual function in the evolution of HI-related brain lesions, particularly, in neonates. On one hand astrocytes can accentuate brain damage by releasing neurotoxic and inflammatory substances (pro-inflammatory cytokines, iNOS), alternatively, they also release beneficial anti-inflammatory cytokines (Sofroniew, 2015). The relative balance of pro-inflammatory and anti-inflammatory cytokines provided by astrocytes probably depends upon the severity of the insult and duration of recovery. Activated astrocytes also release angiogenic factors such as VEGF, which can decrease TJ protein expression and, consequently, increase BBB permeability after stimulating signaling pathways that bind to...
the VEGF-R2 receptor on BECs (Argaw et al., 2012; Argaw, Gurfein, Zhang, Zameer, & John, 2009; Dobrogowska, Lossinsky, Tarnawski, & Vorbrodt, 1998).

Aquaporin 4 (AQ4) is a major water channel in the mammalian brain that is highly expressed on the astrocytes end-foot processes (Chu et al., 2016). Increased AQ4 expression in the early hours after HI injury contributes to the development of edema formation and astrocytic swelling (Fukuda & Badaut, 2012). However, the effects of HI on AQ4 expression in the neonatal brain remain controversial. AQP4 expression increases on astrocytic end-feet in the border regions of injured tissues up to 72 h after injury and normalizes within 28 days after ischemic stroke in neonatal rats (Badaut et al., 2007). Expression of AQ4 expression was also increases in conjunction with MRI determined brain edema. Its expression also increased in the ependyma and meninges but decreased in the striatum of piglets exposed to HI (H. W. Wang, Wang, & Guo, 2012).

### 2.5 Microglia

Perivascular microglia/macrophages are in intimate contact with the BBB, particularly surrounding penetrating vessels and venules, and have a role as the first immune defense against pathogens invading the CNS. Perivascular microglia extend processes that surround brain microvessels and regulate the uptake of some macromolecules (Ransohoff & Perry, 2009). In addition to their role in immune responses, microglia also stimulate angiogenesis via VEGF related mechanisms and secrete multiple trophic factors in developing brain (Mallard, Tremblay, & Vexler, 2018). Microglia are activated within hours after HI-related injury probably because they are the first immune cells to respond to inflammatory signals in the brain (Barrios-Anderson et al., 2019; C. Y. Chen et al., 2015; McRae, Gilland, Bona, & Hagberg, 1995). Microglial morphology changes include increases in the size and ramifications with the development of short thick processes. Their numbers increase and surface proteins and enzyme expression are modified. Activated microglia serve a phagocytic role but also secrete a variety of mediators such as free radicals and pro-inflammatory cytokines that spread inflammatory signals and facilitate recruitment of monocytes/macrophages. Activated microglia also potentiate NVU damage by enhancing MMP-mediated injury (Hagberg, Gressens, & Mallard, 2012; Hagberg et al., 2015; Y. X. Jin, Silverman, & Vannucci, 2009; Lai et al., 2017). They appear as damaging cells after the initial onset of injury. This is consistent with the experimental evidence showing that reduced microglia activation diminishes brain injury (Arvin et al., 2002; Dommergues, Plaisant, Verney, & Gressens, 2003). On the other hand, microglia and other immune cells can also enhance repair in the later phases after injury. Microglial phagocytic activity is crucial to remove cellular debris before tissue remodeling can progress. Complete inhibition of microglial activation has also been shown to result in extensive brain damage after ischemic injury (Faustino et al., 2011; Lalancette-Hebert, Gowing, Simard, Weng, & Kriz, 2007). The mediators controlling the shift from the inflammatory to the repair phase remain to be identified.

The NVU is a complex multicellular system. Each component of the system is interdependent upon the other constituents and, consequently, the function and regulation of the entire system are dependent upon all of its components. Many variables of the NVU
remain to be investigated in the developing brain such as metabolic activities. The most widely reported effects of HI-related insults on the NVU are the increases in the permeability of the BBB. However, the effect of HI injury upon consequences in the later life as well as sex differences remains to be investigated. The effects of HI-related injury upon potential alterations of the NVU in the neonatal brain are graphically summarized in figure 1.

3 | Effect of therapeutic interventions in the NVU

3.1 | Therapeutic hypothermia

The only strategy approved to treat HIE is therapeutic hypothermia. This strategy is only approved to treat full term newborns and is unfortunately only partially protective primarily after exposure to moderate HIE (Gluckman, Gunn, & Wyatt, 2006; Jacobs et al., 2013; Natarajan, Pappas, & Shankaran, 2016; Shankaran, 2012). Minimal changes in body temperature have been shown to affect the function of the BBB (Kiyatkin & Sharma, 2009). Hyperthermia increases albumin extravagation, activates astrocytes and increases markers of brain edema suggesting that increases in body temperatures predispose to BBB leakage (Kiyatkin & Sharma, 2009). However, severe hypothermia also activates glia, induces cellular abnormalities and increases BBB leakage but reduces brain water content. Nonetheless, there is a paucity of information regarding the effects of temperature on the NVU after exposure to HI-related injury in neonates. Therefore, the available information regarding temperature control and the NVU requires extrapolation from studies in vitro and in adult subjects.

Hypothermia initiated soon after ischemia attenuates BBB dysfunction in adult rodents (Baumann, Preston, Slinn, & Stanimirovic, 2009; Preston & Webster, 2004; Zhao et al., 2018). The effects of hypothermia on BBB dysfunction were associated with inhibition of neuroinflammation including decreases in chemokine expression, shifts toward anti-inflammatory microglial phenotypes and reductions in multiple markers of brain injury (Zhao et al., 2018). The effects of in vitro oxygen-glucose deprivation on BECs, astrocytes and neurons are also temperature-dependent (Lyden et al., 2018). Hypothermia prevents pericyte separation from the basement membrane and consequent disorganization of the BECs monolayer after ischemic stroke (Duz et al., 2007). Hypothermia also inhibits the loss of the components such as collagen IV and agrin from the basal lamina (Baumann et al., 2009; Hamann et al., 2004; J. E. Lee, Yoon, Moseley, & Yenari, 2005). Therefore, the neuroprotective efficacy of hypothermia to treat HIE in newborn may be a consequence in part of its effects on the NVU based upon the studies in vitro and in adult subjects summarized above.

3.2 | Erythropoietin

Erythropoietin (EPO) is an attractive anti-inflammatory neuroprotective agent. EPO binds to its receptor expressed on the neuronal membranes, astrocytes and microglial cells to accomplish its anti-inflammatory effects. Numerous studies have shown that EPO attenuates the effects of HI-related injury in neonatal subjects (van der Kooij, Groenendaal, Kavelaars, Heijnen, & van Bel, 2008). However, there is a paucity of information concerning the effects
of EPO on the constituents of the NVU in neonates. Treatment with EPO enhances angiogenesis by stimulating the VEGF signaling pathway in neonatal rodents exposed to anoxia (Yan et al., 2016). It also potentially enhances angiogenic responses by increasing CD34+ cells, VEGF and Ang-1 after exposure to HI in neonatal rats (Zhu et al., 2014) and induces neurogenesis and angiogenesis in vitro in a co-culture system of endothelial and neural progenitor cells derived from the subventricular zone of adult mice (L. Wang et al., 2008). Pretreatment with EPO reduces brain infarct volume and preserves the BBB integrity after ischemic stroke in adult rodents (Bahcekapili, Uzum, Gokkusu, Kuru, & Ziylan, 2007). Treatment after ischemic injury also preserved BBB integrity by reducing TJ degradation and MMP activity (R. L. Wang et al., 2015). Therefore, some of the neuroprotective effects of EPO could be attributed to their effects on the NVU.

3.3 | Other therapeutics

3.3.1 | Stem cell therapy—Stem cell therapy ameliorates neurological deficits after HI-related injury in neonatal subjects (Nabetani, Shintaku, & Hamazaki, 2018). Cell-based therapies derived from umbilical cord blood are rich in endothelial progenitor cells (Pimentel-Coelho, Rosado-de-Castro, da Fonseca, & Mendez-Otero, 2012). Thus, the potential exists that the endothelial cell progenitors have the ability promote neovascularization in tissues damaged by HI. In addition, stem cell therapy has been shown to enhance angiogenesis and reduce damage to the BBB in subjects exposed to HI. Administration of human umbilical vein endothelial cells (HUVECs) attenuates injury to the NVU after exposure to HI (Y. C. Lee, Chang, Wu, & Huang, 2018; Wu et al., 2013). Similarly, treatment with umbilical cord blood CD34+ cells also reduces neuronal damage, decreases astrogliosis and enhances vascular repair after HI (Yu et al., 2018). However, safety profile of stem cell therapy remains to be determined because this therapy could be associated with serious side effects including carcinogenesis and immunosuppression (Titomanlio et al., 2011).

3.3.2 | Anti-cytokines therapy—Targeting pro-inflammatory cytokines could represent a potentially significant therapeutic strategy to treat perinatal HI injury. Recently, we demonstrated encouraging neuroprotective capacities of anti-cytokine monoclonal antibodies (mAbs) after ischemic-reperfusion (I/R) brain injury in the ovine fetus (Disdier, Chen, Kim, Threlkeld, & Stonestreet, 2018). The most important findings were that systemic administration of the anti-IL-1β mAb attenuated brain injury associated with modulation of the neuro-immune response and improved in I/R-related increases in BBB permeability across multiple brain regions measured with an inert non-specific molecule (X. D. Chen et al., 2015). Similarly, we have also shown that systemic infusions of anti-IL-6 mAb diminished the ischemia-related increases in BBB permeability 24 h hours after ischemic injury, modifying tight junction and plasmalemma vesicle protein expression in the fetal brain (J. Y. Zhang et al., 2015).

3.3.3 | Metformin—Metformin is a widely prescribed drug to treat type 2 diabetes mellitus and metabolic syndrome. It has anti-inflammatory and anti-oxidative effects potentially beneficial after exposure to HI in neonates. In adults, metformin has been shown to promote neurogenesis and protect BBB integrity in experimental stroke (Q. Jin et al.,
Treatment with metformin also attenuates tight junction and protein adherens junction degradation, prevents pericyte loss, reduces the astrocyte and microglia activation and down-regulates neuro-inflammation after HI in neonatal rodents (Fang et al., 2017).

### 3.3.4 Other potential therapeutics

Other studies have attempted to attenuate HI related brain injury (Nair & Kumar, 2018). Xenon, N-acetylcysteine and melatonin are free radical scavengers that have demonstrated promising neuroprotective effects in animal models of HI-related brain injury. These agents have demonstrated beneficial effects by reducing microglial activation or astrogliosis. However, studies have not examined the effects of these agents specifically on changes on the elements of the NVU after exposure the HI related injury in the neonatal brain. Single-cell technologies especially single-cell RNA sequencing could help to identify cell-specific variables such as patterns of mRNA and protein expression in the developing brain with respect to the organizational hierarchy and structural diversity of cells in context with brain injury (Fan et al., 2018; Grant et al., 2019; Q. Mu, Chen, & Wang, 2019; Polioudakis et al., 2019). These findings could probably help to identify highly selective pharmacological targets for perinatal astrocytes, microglia and other cellular components of NVU considering the complex interactions among elements of the NVU system.

### 3 Conclusions

Exposure to HI initiates a wide variety of deleterious effects on the neonatal brain resulting in long-term consequences later in life. The NVU represents an important component in the pathophysiology of neonatal HI-related brain injury. However, many characteristics of the NVU remain to be elucidated after exposure to HI. Although BBB permeability increases immediately after the onset of HI in perinatal brain, there is a paucity of knowledge regarding its effects on transport function and metabolism in BECs. Similarly, studies are still required to understand the impact of HI on other components of NVU as well as their interactions and role of this system during development. Prevention of neurovascular damage or enhancement of repair represents a potentially important therapeutic strategy to attenuate brain injury.

### ACKNOWLEDGEMENTS

This work was supported by National Institutes of Health (NIH) National Institute of General Medical Sciences of the National Institutes of Health: Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P30GM114750, National Institutes of Health 1R21NS095130, 1R21NS096525, R44 NS084575 and 2R01HD057100.

Funding information:

This work was supported by National Institutes of Health (NIH) National Institute of General Medical Sciences of the National Institutes of Health: National Institutes of Health 1R21NS095130, 1R21NS096525, R44 NS084575 and 2R01HD057100.

### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| BBB          | Blood-Brain Barrier |
CNS  Central Nervous System
BEC  Brain endothelial cell
NVU  Neuro-vascular Unit
ECM  Extracellular Matrix
HI   Hypoxia ischemia
HIE  Hypoxic-ischemic encephalopathy
TJ   Tight junction
SLC  Solute carrier
ABC  ATP binding cassette
VEGF Vascular endothelial growth factor
FGF-2 fibroblast growth factor 2
MMP  Matrix metalloproteinases
HIF-1α Hypoxia-inducible factor 1-alpha
GFAP Glial fibrillary acidic protein
AQ4 Aquaporine 4
EPO  erythropoietin

REFERENCES

Abbott NJ (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. Journal of Anatomy, 200(6), 629–638. doi:10.1046/j.1469-7580.2002.00064.x [PubMed: 12162730]
Abbott NJ, & Friedman A (2012). Overview and introduction: The blood-brain barrier in health and disease. Epilepsia, 53, 1–6. doi:10.1111/j.1528-1167.2012.03696.x
Al Ahmad A, Taboada CB, Gassmann M, & Ogunshola OO (2011). Astrocytes and pericytes differentially modulate blood-brain barrier characteristics during development and hypoxic insult. Journal of Cerebral Blood Flow and Metabolism, 31(2), 693–705. doi:10.1038/jcbfm.2010.148 [PubMed: 20827262]
Alotaibi M, Arrowsmith S, & Wray S (2015). Hypoxia-induced force increase (HIFI) is a novel mechanism underlying the strengthening of labor contractions, produced by hypoxic stresses. Proceedings of the National Academy of Sciences of the United States of America, 112(31), 9763–9768. doi:10.1073/pnas.1503497112 [PubMed: 26195731]
Aly H, Khashaba MT, Nada A, Hasanen BM, McCarter R, Schultz SJ, … Lassiter HA (2009). The Role of Complement in Neurodevelopmental Impairment following Neonatal Hypoxic-Ischemic Encephalopathy. American Journal of Perinatology, 26(9), 659–665. doi:10.1055/s-0029-1220793 [PubMed: 19391086]
Anstrom JA, Thore CR, Moody DM, & Brown WR (2007). Immunolocalization of tight junction proteins in blood vessels in human germinal matrix and cortex. Histochemistry and Cell Biology, 127(2), 205–213. doi:10.1007/s00418-006-0232-z [PubMed: 16957815]
Argaw AT, Asp L, Zhang JY, Navrazhina K, Pham T, Mariani JN, … John GR (2012). Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. Journal of Clinical Investigation, 122(7), 2454–2468. doi:10.1172/jci60842 [PubMed: 22653056]

J Neurosci Res. Author manuscript; available in PMC 2021 January 01.
Argaw AT, Gurfein BT, Zhang YT, Zameer A, & John GR (2009). VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proceedings of the National Academy of Sciences of the United States of America, 106(6), 1977–1982. doi:10.1073/pnas.0808698106 [PubMed: 19174516]

Arvin KL, Han BH, Du YS, Lin SZ, Paul SM, & Holtzman DM (2002). Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Annals of Neurology, 52(1), 54–61. doi:10.1002/ana.10242 [PubMed: 12112047]

Ashwal S, & Pearce WJ (2001). Animal models of neonatal stroke. Curr Opin Pediatr, 13(6), 506–516. doi:10.1097/00008480-200112000-00003 [PubMed: 11753098]

Azizopordi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, … Brocklehurst P (2010). Moderate Hypothermia to Treat Perinatal Asphyxial Encephalopathy (vol 361, pg 1349, 2009). New England Journal of Medicine, 362(11), 1056–1056.

Baburamani AA, Castillo-Melendez M, & Walker DW (2013). VEGF expression and microvascular responses to severe transient hypoxia in the fetal sheep brain. Pediatr Res, 73(3), 310–316. doi:10.1038/pr.2012.191 [PubMed: 23222909]

Baburamani AA, Ek CJ, Walker DW, & Castillo-Melendez M (2012). Vulnerability of the developing brain to hypoxic-ischemic damage: contribution of the cerebral vasculature to injury and repair? Frontiers in Physiology, 3. doi:10.3389/fphys.2012.00424

Baburamani AA, Lo C, Castillo-Melendez M, & Walker DW (2013). Morphological evaluation of the cerebral blood vessels in the late gestation fetal sheep following hypoxia in utero. Microvascular Research, 85, 1–9. doi:10.1016/j.mvr.2012.09.007 [PubMed: 23041509]

Back SA (2006). Perinatal white matter injury: The changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Mental Retardation and Developmental Disabilities Research Reviews, 12(2), 129–140. doi:10.1002/mrdd.20107 [PubMed: 16807910]

Back SA (2015). Brain Injury in the Preterm Infant: New Horizons for Pathogenesis and Prevention. Pediatr Neurol, 53(3), 185–192. doi:10.1016/j.pediatrneurol.2015.04.006 [PubMed: 26302698]

Back SA, & Miller SP (2014). Brain injury in premature neonates: A primary cerebral dysmaturation disorder? Ann Neurol, 75(4), 469–486. doi:10.1002/ana.24132 [PubMed: 24615937]

Badat J, Ashwal S, Tone B, Regli L, Tian HR, & Obenaus A (2007). Temporal and regional evolution of aquaporin-4 expression and magnetic resonance imaging in a rat pum model of neonatal stroke. Pediatr Res, 62(3), 248–254. doi:10.1203/PDR.0b013e3180db291b [PubMed: 17622964]

Bahcekapili N, Uzum G, Gokkusu C, Kuru A, & Ziylan YZ (2007). The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats. Life Sciences, 80(14), 1245–1251. doi:10.1016/j.lfs.2006.12.014 [PubMed: 17300815]

Ballabh P, Braun A, & Nedergaard M (2004). The blood-brain barrier: an overview - Structure, regulation, and clinical implications. Neurobiology of Disease, 16(1), 1–13. doi:10.1016/j.nbd.2003.12.016 [PubMed: 15207256]

Ballabh P, Hu F, Kumarasiri M, Braun A, & Nedergaard M (2005). Development of tight junction molecules in blood vessels of germinal matrix, cerebral cortex, and white matter. Pediatr Res, 58(4), 791–798. [PubMed: 16189211]

Bandopadhyay R, Orte C, Lawrenson JG, Reid AR, De Silva S, & Allt G (2001). Contractile proteins in pericytes at the blood-brain and blood-retinal barriers. Journal of Neurocytology, 30(1), 35–44. doi:10.1023/a:1011965307612 [PubMed: 11577244]

Banks WA (2010). Blood-Brain Barrier as a Regulatory Interface. Frontiers in Eating and Weight Regulation, 63, 102–110.

Banks WA, Kastin AJ, & Broadwell RD (1995). Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation, 2(4), 241–248. doi:10.1159/000097202 [PubMed: 8963753]

Bankstahl M, Breuer H, Leiter I, Markel M, Bascunana P, Michalski D, … Hartig W (2018). Blood-Brain Barrier Leakage during Early Epileptogenesis Is Associated with Rapid Remodeling of the Neurovascular Unit. Eneuro, 5(3). doi:10.1523/eneuro.0123-18.2018

Barrios-Anderson A, Chen X, Nakada S, Chen R, Lim YP, & Stonestreet BS (2019). Inter-alpha Inhibitor Proteins Modulate Neuroinflammatory Biomarkers After Hypoxia-Ischemia in Neonatal Rats. J Neuropathol Exp Neurol. doi:10.1093/jnen/nlz051

J Neurosci Res. Author manuscript; available in PMC 2021 January 01.
Bartha AI, Foster-Barber A, Miller SP, Vigneron DB, Barkovich AJ, & Ferriero DM (2004). Neonatal encephalopathy: Association of cytokines with MR spectroscopy and outcome. Pediatr Res, 56(6), 960–966. doi:10.1203/01.pdr.0000144819.45689.bb [PubMed: 15496611]

Bauer HC, Bauer H, Lametschwandtner A, Amberger A, Ruiz P, & Steiner M (1993). Neovascularization and the appearance of morphological characteristics of the blood-brain barrier in the embryonic mouse central nervous system. Brain Res Dev Brain Res, 75(2), 269–278. [PubMed: 8261616]

Baumann E, Preston E, Slinn J, & Stanimirovic D (2009). Post-ischemic hypothermia attenuates loss of the vascular basement membrane proteins, agrin and SPARC, and the blood-brain barrier disruption after global cerebral ischemia. Brain Research, 1269, 185–197. doi:10.1016/j.brainres.2009.02.062 [PubMed: 19285050]

Bonmans C, Chou J, & Werb Z (2014). Remodelling the extracellular matrix in development and disease. Nature Reviews Molecular Cell Biology, 15(12), 786–801. doi:10.1038/nrm3904 [PubMed: 25415508]

Cardoso FL, Brites D, & Brito MA (2010). Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Research Reviews, 64(2), 328–363. doi:10.1016/j.brainresrev.2010.05.003 [PubMed: 20685221]

Cen J, Liu L, Li MS, He L, Wang LJ, Liu YQ, … Ji BS (2013). Alteration in P-glycoprotein at the bloodbrain barrier in the early period of MCAO in rats. Journal of Pharmacy and Pharmacology, 65(5), 665–672. doi:10.1111/jpph.12033 [PubMed: 23600383]

Charriaut-Marlangue C, Besson CV, & Baud O (2018). Sexually Dimorphic Outcomes after Neonatal Stroke and Hypoxia-Isschemia. International Journal of Molecular Sciences, 19(1). doi:10.3390/ijms19010061

Chavez-Valdez R, Martin LJ, Flock DL, & Northington FJ (2012). NECROSTATIN-1 ATTENUATES MITOCHONDRIAL DYSFUNCTION IN NEURONS AND ASTROCYTES FOLLOWING NEONATAL HYPOXIA-ISCHEMIA. Neuroscience, 219, 192–203. doi:10.1016/j.neuroscience.2012.05.002 [PubMed: 22579794]

Chen CY, Sun WZ, Kang KH, Chou HC, Tsao PN, Hsieh WS, & Fu WM (2015). Hypoxic Preconditioning Suppresses Glial Activation and Neuroinflammation in Neonatal Brain Insults. Mediators of Inflammation. doi:10.1155/2015/632592

Chen WQ, Hartman R, Ayer R, Marcantonio S, Kamper J, Tang JP, & Zhang JH (2009). Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. Journal of Neurochemistry, 111(3), 726–736. doi:10.1111/j.1471-4159.2009.06362.x [PubMed: 19712057]

Chen X, Patra A, Sadowska GB, & Stonestreet BS (2018). Ischemic-Reperfusion Injury Increases Matrix Metalloproteinases and Tissue Metalloproteinase Inhibitors in Fetal Sheep Brain. Dev Neurosci, 40(3), 234–245. doi:10.1159/000489700 [PubMed: 30048980]

Chen XD, Sadowska GB, Zhang JY, Kim JE, Cummings EE, Bodge CA, … Stonestreet BS (2015). Neutralizing anti-interleukin-1 beta antibodies modulate fetal blood-brain barrier function after ischemia. Neurobiology of Disease, 73, 118–129. doi:10.1016/j.nbd.2014.09.007 [PubMed: 25258170]

Chu HL, Huang CY, Ding HY, Dong J, Gao ZD, Yang XB, … Dong Q (2016). Aquaporin-4 and Cerebrovascular Diseases. International Journal of Molecular Sciences, 17(8). doi:10.3390/ijms17081249

Clancy B, Darlington RB, & Finlay BL (2001). Translating developmental time across mammalian species. Neuroscience, 105(1), 7–17. doi:10.1016/s0306-4522(01)00171-3 [PubMed: 11483296]

Clancy B, Finlay BL, Darlington RB, & Arland KJS (2007). Extrapolating brain development from experimental species to humans. Neurotoxicology, 28(5), 931–937. doi:10.1016/j.neuro.2007.01.014 [PubMed: 17368774]

Conklin HM, Salorio CF, & Slomine BS (2008). Working memory performance following paediatric traumatic brain injury. Brain Injury, 22(11), 847–857. doi:10.1080/02699050802403565 [PubMed: 18850343]

Cui X, Chopp M, Zacharek A, Karasinska JM, Cui YS, Ning RZ, … Chen JL (2015). Deficiency of Brain ATP-Binding Cassette Transporter A-1 Exacerbates Blood-Brain Barrier and White Matter Dysfunction in MCAO. Stroke, 46(7), 1996–2002. doi:10.1161/STROKEAHA.115.010073 [PubMed: 26030332]
Damage After Stroke. Stroke, 46(3), 827–834. doi:10.1161/strokeaha.114.007145 [PubMed: 25593138]

Dalkara T, Gursoy-Ozdemir Y, & Yemisci M (2011). Brain microvascular pericytes in health and disease. Acta Neuropathologica, 122(1), 1–9. doi:10.1007/s00401-011-0847-6 [PubMed: 21656168]

Daneman R, Zhou L, Agalli D, Cahoy JD, Kaushal A, & Barres BA (2010). The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells. Plos One, 5(10). doi:10.1371/journal.pone.0013741 [PubMed: 21656168]

Danaei G, Rehm J, Popkin BM, et al. (2008). Cancer, cardiovasc, and other non-communicable diseases attributable to poor diet in 216 countries, 1986-2005: A systematic analysis. Lancet, 372(9634), 519–542. doi:10.1016/s0140-6736(08)61466-4 [PubMed: 18746668]

Daneman R, Zhou L, Kebede AA, & Barres BA (2010). Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature, 468(7323), 562–U238. doi:10.1038/nature09513 [PubMed: 20944625]

Dazert P, Suofu Y, Grube M, Popa-Wagner A, Kroemer HK, Jedlitschky G, & Kessler C (2006). Differential regulation of transport proteins in the perifibract region following reversible middle cerebral artery occlusion in rats. Neuroscience, 142(4), 1071–1079. doi:10.1016/j.neuroscience.2006.07.056 [PubMed: 16997484]

Decleves X, Jacob A, Yousif S, Shawahna R, Potin S, & Scherrmann JM (2011). Interplay of Drug Metabolizing CYP450 Enzymes and ABC Transporters in the Blood-Brain Barrier: Current Drug Metabolism, 12(8), 732–741. [PubMed: 21623707]

Dente CJ, Steffes CP, Spery C, & Tyburski JG (2001). Pericytes augment the capillary barrier in vitro cocultures. Journal of Surgical Research, 97(1), 85–91. doi:10.1006/jsre.2001.6117 [PubMed: 11319886]

Dent C, Chen XD, Kim JE, Threlkeld SW, & Stonestreet BS (2018). Anti-Cytokine Therapy to Attenuate Ischemic-Reperfusion Associated Brain Injury in the Perinatal Period. Brain Sciences, 8(6). doi:10.3390/brainsci8060101

Dobbing J, & Sands J (1979). COMPARATIVE ASPECTS OF THE BRAIN GROWTH SPURT. Early Human Development, 8(1), 79–83. doi:10.1016/0378-3782(79)90022-7

Dobrogowska DH, Lossinsky AS, Tarnawski M, & Vorbrodt AW (1998). Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. Journal of Neurocytology, 27(3), 163–173. doi:10.1023/a:1006907608230 [PubMed: 10640176]

Dommergues MA, Plaisant F, Verney C, & Gressens P (2003). Early microglial activation following neonatal excitotoxic brain damage in mice: A potential target for neuroprotection. Neuroscience, 121(3), 619–628. doi:10.1016/s0306-4522(03)00558-x [PubMed: 14568022]

Dore-Duffy P (2008). Pericytes: Pluripotent cells of the blood brain barrier. Current Pharmaceutical Design, 14(16), 1581–1593. doi:10.2174/138161208784705469 [PubMed: 18673199]

Dore-Duffy P, & Cleary K (2011). Morphology and properties of pericytes. Methods in molecular biology (Clifton, N.J.), 686, 49–68. doi:10.1007/978-1-60761-938-3_2

Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, & Rafols JA (2000). Pericyte migration from the vascular wall in response to traumatic brain injury. Microvascular Research, 60(1), 55–69. doi:10.1006/mvre.2000.2244 [PubMed: 10873515]

Duz B, Oztas E, Erginay T, Erdogan E, & Gonul E (2007). The effect of moderate hypothermia in acute ischemic stroke on pericyte migration: An ultrastructural study. Cryobiology, 55(3), 279–284. doi:10.1016/j.cryobiol.2007.08.009 [PubMed: 17923122]

Eisenblatter T, Huwel S, & Gallia HJ (2003). Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Research, 971(2), 221–231. doi:10.1016/s0006-8993(03)02401-6 [PubMed: 12706238]

Ek CJ, D’Angelo B, Baburamani AA, Lehner C, Leverin AL, Smith PLP, … Mallard C (2015). Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia. Journal of Cerebral Blood Flow and Metabolism, 35(5), 818–827. doi:10.1038/jcbfm.2014.255 [PubMed: 25627141]

Ek CJ, D’Angelo B, Lehner C, Nathanielsz P, Li C, & Mallard C (2015). Expression of tight junction proteins and transporters for xenobiotic metabolism at the blood-CSF barrier during development in the nonhuman primate (P. hamadryas). Reproductive Toxicology, 56, 32–44. doi:10.1016/j.reprotox.2015.06.047 [PubMed: 26092209]
Ek CJ, Dziegielewska KM, Habgood MD, & Saunders NR (2012). Barriers in the developing brain and Neurotoxicology. Neurotoxicology, 33(3), 586–604. doi:10.1016/j.neuro.2011.12.009 [PubMed: 22198708]

Ek CJ, Dziegielewska KM, Stolp H, & Saunders NR (2006). Functional effectiveness of the blood brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). Journal of Comparative Neurology, 496(1), 13–26. doi:10.1002/cne.20885 [PubMed: 16528724]

Ek CJ, Habgood MD, Dziegielewska KM, & Saunders NR (2003). Structural characteristics and barrier properties of the choroid plexuses in developing brain of the opossum (Monodelphis domestica). Journal of Comparative Neurology, 460(4), 451–464. doi:10.1002/cne.10661 [PubMed: 12717706]

Ek CJ, Wong A, Liddelow SA, Johansson PA, Dziegielewska KM, & Saunders NR (2010). Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicology Letters, 197(1), 51–59. doi:10.1016/j.toxlet.2010.04.025 [PubMed: 20466047]

El-Bacha RS, & Minn A (1999). Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cellular and Molecular Biology, 45(1), 15–23. [PubMed: 10099836]

Engelhardt S, Huang SF, Patkar S, Gassmann M, & Ogunshola OO (2015). Differential responses of blood-brain barrier associated cells to hypoxia and ischemia: a comparative study. Fluids and Barriers of the Cns, 12. doi:10.1371/journal.pone.0205769

Erickson MA, Liang WS, Fernandez EG, Bullock KM, Thysell JA, & Banks WA (2018). Genetics and sex influence peripheral and central innate immune responses and blood-brain barrier integrity. Plos One, 13(10). doi:10.1371/journal.pone.0205769

Fan X, Dong J, Zhong S, Wei Y, Wu Q, Yan L, … Tang F (2018). Spatial transcriptomic survey of human embryonic cerebral cortex by single-cell RNA-seq analysis. Cell Res, 28(7), 730–745. doi:10.1038/s41422-018-0053-3 [PubMed: 29867213]

Fang MC, Jiang HA, Ye LX, Cai CC, Hu YY, Pan SL, … Lin ZL (2017). Metformin treatment after the hypoxia-ischemia attenuates brain injury in newborn rats. Oncotarget, 8(43), 75308–75325. doi:10.18632/oncotarget.20779 [PubMed: 29088867]

Fatemi A, Wilson MA, & Johnston MV (2009). Hypoxic-Ischemic Encephalopathy in the Term Infant. Clinics in Perinatology, 36(4), 835+. doi:10.1016/j.clp.2009.07.011 [PubMed: 19944838]

Faustino JV, Wang X, Johnson CE, Klibanov A, Derugin N, Wendland MF, & Vexler ZS (2011). Microglial Cells Contribute to Endogenous Brain Defenses after Acute Neonatal Focal Stroke. Journal of Neuroscience, 31(36), 12992–13001. doi:10.1523/jneurosci.2102-11.2011 [PubMed: 21900578]

Fernandez-Klett F, Potas JR, Hilpert D, Blazej K, Radke J, Huck J, … Priller J. (2013). Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. Journal of Cerebral Blood Flow and Metabolism, 33(3), 428–439. doi: 10.1038/jcbfm.2012.187 [PubMed: 23250106]

Ferriero DM (2004). Neonatal brain injury. New England Journal of Medicine, 351(15), 1644–1644.

Gonul E, Duz B, Kahraman S, Kayali H, Kubar A, & Timurkaynak E (2002). Early pericyte response to brain hypoxia in cats: An ultrastructural study. Microvascular Research, 64(1), 116–119. doi:10.1006/mvre.2002.2413 [PubMed: 12074637]
and gray matter: potential mechanism of increased vulnerability in the immature brain. Cereb Cortex, 25(2), 482–495. doi:10.1093/cercor/bht246 [PubMed: 24046081]

Jin Q, Cheng J, Liu Y, Wu J, Wang XY, Wei SW, … Zhen XC (2014). Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behavior and Immunity, 40, 131–142. doi:10.1016/j.bbi.2014.03.003

Jin YX, Silverman AJ, & Vannucci SJ (2009). Mast Cells Are Early Responders After Hypoxia-Ischemia in Immature Rat Brain. Stroke, 40(9), 3107–3112. doi:10.1161/strokeaha.109.549691 [PubMed: 19520991]

Kaur C, & Ling EA (2008). Blood brain barrier in hypoxic-ischemic conditions. Current Neurovascualar Research, 5(1), 71–81. doi:10.2174/156720200783565645 [PubMed: 18289024]

Kharoshankaya L, Stevenson NJ, Livingstone V, Murray DM, Murphy BP, Ahearne CE, & Boylan GB (2016). Seizure burden and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Developmental Medicine and Child Neurology, 58(12), 1242–1248. doi:10.1111/dmcn.13215 [PubMed: 27595841]

Kim SH, Turnbull J, & Guimond S (2011). Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. Journal of Endocrinology, 209(2), 139–151. doi:10.1530/joe-10-0377 [PubMed: 21307119]

Kimelberg HK, & Nedergaard M (2010). Functions of Astrocytes and their Potential As Therapeutic Targets. Neurotherapeutics, 7(4), 338–353. doi:10.1016/j.nurt.2010.07.006 [PubMed: 20880499]

Kiyatkin EA, & Sharma HS (2009). PERMEABILITY OF THE BLOOD-BRAIN BARRIER DEPENDS ON BRAIN TEMPERATURE. Neuroscience, 161(3), 926–939. doi:10.1016/j.neuroscience.2009.04.004 [PubMed: 19362131]

Kniesel U, Risau W, & Wolburg H (1996). Development of blood-brain barrier tight junctions in the rat cortex. Developmental Brain Research, 96(1–2), 229–240. doi:10.1016/s0165-3806(96)00117-4 [PubMed: 8922685]

Koehler RC, Yang ZJ, Lee JK, & Martin LJ (2018). Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy. J Cereb Blood Flow Metab, 38(12), 2092–2111. doi:10.1016/j.jcbfm.2018.09.004 [PubMed: 30149778]

Kumar A, Mittal R, Khanna HD, & Basu S (2008). Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. Pediatrics, 122(3), E722–E727. doi:10.1542/peds.2008-0269 [PubMed: 18725389]

Lai JCY, Rocha-Ferreira E, Ek CJ, Wang XY, Hagberg H, & Mallard C (2017). Immune responses in perinatal brain injury. Brain Behavior and Immunity, 63, 210–223. doi:10.1016/j.bbi.2016.10.022

Lalancette-Hebert M, Gowing G, Simard A, Weng YC, & Kriz J (2007). Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. Journal of Neuroscience, 27(10), 2596–2605. doi:10.1523/jneurosci.5360-06.2007 [PubMed: 17344397]

Lam J, Baello S, Iqbal M, Kelly LE, Shannon PT, Chitayat D, … Koren G (2015). The ontology of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res, 78(4), 417–421. doi:10.1038/pr.2015.119 [PubMed: 26086643]

Lee JE, Yoon YJ, Moseley ME, & Yenari MA (2005). Reduction in levels of matrix metalloproteinases and increased expression of tissue inhibitor of metalloproteinase-2 in response to mild hypothermia therapy in experimental stroke. Journal of Neurosurgery, 103(2), 289–297. doi:10.3171/jns.2005.103.2.0289

Lee YC, Chang YC, Wu CC, & Huang CC (2018). Hypoxia-Preconditioned Human Umbilical Vein Endothelial Cells Protect Against Neurovascular Damage After Hypoxic Ischemia in Neonatal Brain. Molecular Neurobiology, 55(10), 7743–7757. doi:10.1007/s12035-018-0867-5 [PubMed: 29460267]

Leonardo CC, Eakin AK, Ajmo JM, Collier LA, Pennypacker KR, Strongin AY, & Gottschall PE (2008). Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat. Journal of Neuroinflammation, 5. doi:10.1186/1742-2094-5-34

Liu FD, & McCullough LD (2013). Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacologica Sinica, 34(9), 1121–1130. doi:10.1038/aps.2013.89 [PubMed: 23892271]
Lu JJ, Jiang L, Zhu H, Zhang L, & Wang T (2014). Hypoxia-Inducible Factor-1 alpha and Erythropoietin Expression in the Hippocampus of Neonatal Rats Following Hypoxia-Ischemia. Journal of Nanoscience and Nanotechnology, 14(8), 5614–5619. doi:10.1166/jnn.2014.8728 [PubMed: 25935977]

Lyden PD, Lamb J, Kothari S, Toossi S, Boitano P, & Rajput PS (2018). Differential effects of hypothermia on neurovascular unit determine protective or toxic results: Toward optimized therapeutic hypothermia. J Cereb Blood Flow Metab, 271678×18814614. doi:10.1177/0271678×18814614

Lyons MK, Anderson RE, & Meyer FB (1991). BASIC FIBROBLAST GROWTH-FACTOR PROMOTES INVIVO CEREBRAL ANGIGENESIS IN CHRONIC FOREBRAIN ISCHEMIA. Brain Research, 558(2), 315–320. doi:10.10160006-8993(91)90784-s [PubMed: 1723639]

Ma QY, Dasgupta C, Li Y, Huang L, & Zhang LB (2017). MicroRNA-210 Suppresses Junction Proteins and Disrupts Blood-Brain Barrier Integrity in Neonatal Rat Hypoxic-Ischemic Brain Injury. International Journal of Molecular Sciences, 18(7). doi:10.3390/ijms18071356

MacLennan AH, Thompson SC, & Gezcz J (2015). Cerebral palsy: causes, pathways, and the role of genetic variants. American Journal of Obstetrics and Gynecology, 213(6), 779–788. doi:10.1016/j.ajog.2015.05.034 [PubMed: 26003063]

Malae SN, Sadowska GB, & Stonestreet BS (2007). Effects of maternal treatment with corticosteroids on tight junction protein expression in the cerebral cortex of the ovine fetus with and without exposure to in utero brain ischemia. Brain Research, 1160, 11–19. doi:10.1016/j.brainres.2007.05.043 [PubMed: 17583681]

Mallard C, Tremblay ME, & Vexler ZS (2018). Microglia and Neonatal Brain Injury. Neuroscience. doi:10.1016/j.neuroscience.2018.01.023

Marchi N, Granata T, Ghosh C, & Janigro D (2012). Blood-brain barrier dysfunction and epilepsy: Pathophysiologic role and therapeutic approaches. Epilepsia, 53(11), 1877–1886. doi:10.1111/j.1528-1167.2012.03637.x [PubMed: 22905812]

Mathiisen TM, Lehre KP, Danbolt NC, & Ottersen OP (2010). The Perivascular Astroglial Sheath Provides a Complete Covering of the Brain Microvessels: An Electron Microscopic 3D Reconstruction. Glia, 58(9), 1094–1103. doi:10.1002/glia.20990 [PubMed: 20468051]

McRae A, Gilland E, Bona E, & Hagberg H (1995). MICROGLIA ACTIVATION AFTER NEONATAL HYPOXIC-ISCHEMIA. Developmental Brain Research, 84(2), 245–252. doi:10.10160165-3806(94)00177-2 [PubMed: 7743644]

Millar LJ, Shi L, Hoerder-Suabedissen A, & Molnar Z (2017). Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges. Frontiers in Cellular Neuroscience, 11. doi:10.3389/fncel.2017.00078

Miller DS (2015). Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly. Advances in cancer research, 125, 43–70. doi:10.1016/bs.acr.2014.10.002 [PubMed: 25640266]

Mollgard K, Dziegielew ska KM, Holst CB, Habgood MD, & Saunders NR (2017). Brain barriers and functional interfaces with sequential appearance of ABC efflux transporters during human development. Scientific Reports, 7. doi:10.1038/s41598-017-11596-0

Moretti R, Pansiot J, Bettati D, Strazielle N, Ghersi-Egea JF, Damante G, … Gressens (2015). Blood-brain barrier dysfunction in disorders of the developing brain. Frontiers in Neuroscience, 9. doi:10.3389/fnins.2015.00040

Mu DZ, Jiang XN, Sheldon RA, Fox CK., Hamrick SEG, Vexler ZS, & Ferriero DM (2003). Regulation of hypoxia-inducible factor 1 alpha and induction of vascular endothelial growth factor in a rat neonatal stroke model. Neurobiology of Disease, 14(3), 524–534. doi:10.1016/j.nbd.2003.08.020 [PubMed: 14678768]

Mu Q, Chen Y, & Wang J (2019). Deciphering Brain Complexity Using Single-cell Sequencing. Genomics Proteomics Bioinformatics, 17(4), 344–366. doi:10.1016/j.gpb.2018.07.007 [PubMed: 31586689]
Munji RN, Soung AL, Weiner GA, Sohet F, Semple BD, Trivedi A, … Daneman R (2019). Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module. Nat Neurosci. doi:10.1038/s41593-019-0497-x

Muramatsu K, Fukuda A, Togari H, Wada Y, & Nishino H (1997). Vulnerability to cerebral hypoxic-ischemic insult in neonatal but not in adult rats is in parallel with disruption of the blood-brain barrier. Stroke, 28(11), 2281–2288; discussion 2288–2289. [PubMed: 9368577]

Nabetani M, Shintaku H, & Hamazaki T (2018). Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. Pediatr Res. 88(1), 356–363. doi:10.1038/pr.2017.260

Nagase H, Visse R, & Murphy G (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 69(3), 562–573. doi:10.1016/j.cardiores.2005.12.002 [PubMed: 16405877]

Nair J, & Kumar VHS (2018). Current and Emerging Therapies in the Management of Hypoxic Ischemic Encephalopathy in Neonates. Children (Basel), 5(7). doi:10.3390/children5070099

O’Brown NM, Pfau SJ, & Gu C (2018). Bridging barriers: a comparative look at the blood-brain barrier across organisms. Genes Dev, 32(7–8), 466–478. doi:10.1101/gad.309823.117 [PubMed: 29692355]

Oberheim NA, Wang X, Goldman S, & Nedergaard M (2006). Astrocytic complexity distinguishes the human brain. Trends Neurosci, 29(10), 547–553. doi:10.1016/j.tins.2006.08.004 [PubMed: 16938356]

Patra A, Chen XD, Sadowska GB, Zhang JY, Lim YP, Padbury JF, … Stonestreet BS (2017). Neutralizing anti-interleukin-1 beta antibodies reduce ischemia-related interleukine-1 beta transport across the Blood-Brain barrier in fetal sheep. Neuroscience, 346, 113–125. doi:10.1016/j.neuroscience.2016.12.051 [PubMed: 28089577]

Pimentel-Coelho PM, Rosado-de-Castro PH, da Fonseca LMB, & Mendez-Otero R (2012). Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatr Res, 71(4), 464–473. doi:10.1038/pr.2011.59 [PubMed: 22430382]

Polioudakis D, de la Torre-Ubieta L, Langerman J, Elkins AG, Shi X, Stein JL, … Geschwind DH (2019). A Single-Cell Transcriptomic Atlas of Human Neocortical Development during Mid-gestation. Neuron, 103(5), 785–801 e788. doi:10.1016/j.neuron.2019.06.011 [PubMed: 31303374]

Qiu L, Zhu CL, Wang XY, Xu FL, Eriksson PS, Nilsson M, … Blomgren K (2007). Less neurogenesis and inflammation in the immature than in the juvenile brain after cerebral hypoxia-ischemia.
Soares RV, Do TM, Mabondzo A, Pons G, & Chhun S (2016). Ontogeny of ABC and SLC transporters in the microvessels of developing rat brain. Fundamental & Clinical Pharmacology, 30(2), 107–116. doi:10.1111/fcp.12175 [PubMed: 26662930]

Sofroniew MV (2015). Astrocyte barriers to neurotoxic inflammation. Nature Reviews Neuroscience, 16(5), 249–263. doi:10.1038/nrn3898 [PubMed: 25891508]

Spudich A, Kilic E, Xing HY, Kilic U, Rentsch KM, Wunderli-Allenspach H, … Hermann DM (2006). Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nature Neuroscience, 9(4), 487–488. doi:10.1038/nn1676 [PubMed: 16565717]

Stanimirovic D, & Satoh K (2000). Inflammatory mediators of cerebral endothelium: A role in ischemic brain inflammation. Brain Pathology, 10(1), 113–126. [PubMed: 10668901]

Strazielle N, & Ghersi-Egea JF (2015). Efflux transporters in blood-brain interfaces of the developing brain. Frontiers in Neuroscience, 9. doi:10.3389/fnins.2015.00021

Sullivan SM, Bjorkman ST, Miller SM, Colditz PB, & Pow DV (2010). Morphological changes in white matter astrocytes in response to hypoxia/ischemia in the neonatal pig. Brain Research, 1319, 164–174. doi:10.1016/j.brainres.2010.01.010 [PubMed: 20079338]

Svedin P, Hagberg H, Savman K, Zhu CL, & Mallard C (2007). Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. Journal of Neuroscience, 27(7), 1511–1518. doi:10.1523/jneurosci.4391-06.2007 [PubMed: 17301159]

Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, & Stinson DA (2012). Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy An Updated Systematic Review and Meta-analysis. Archives of Pediatrics & Adolescent Medicine, 166(6), 558–566. doi:10.1001/archpediatrics.2011.1772 [PubMed: 22312166]

Takata F, Dougu S, Matsumoto J, Machida T, Kaneshima S, Matsuo M, … Kataoka Y (2013). Metformin induces up-regulation of blood-brain barrier functions by activating AMP-activated protein kinase in rat brain microvascular endothelial cells. Biochemical and Biophysical Research Communications, 433(4), 586–590. doi:10.1016/j.bbrc.2013.03.036 [PubMed: 23523792]

Tang BZ, Wang DJ, Li MJ, Wu Q, Yang Q, Shi W, & Chen CH (2017). An in vivo study of hypoxia-inducible factor-1 alpha signaling in ginsenoside Rg1-mediated brain repair after hypoxia/ischemia brain injury. Pediatr Res, 81(1), 120–126. doi:10.1038/pr.2016.178 [PubMed: 27632778]

Teo JD, Morris MJ, & Jones NM (2015). Hypoxic postconditioning reduces microglial activation, astrocyte and caspase activity, and inflammatory markers after hypoxia-ischemia in the neonatal rat brain. Pediatr Res, 77(6), 757–764. doi:10.1038/pr.2015.47 [PubMed: 25751571]

Threlkeld SW, Lynch JL, Lynch KM, Sadowska GB, Banks WA, & Stonestreet BS (2010). Ovine Proinflammatory Cytokines Cross the Murine Blood-Brain Barrier by a Common Saturable Transport Mechanism. Neuroimmunomodulation, 17(6), 405–410. doi:10.1159/000288265 [PubMed: 20516722]

Titomanlio L, Kavalaars A, Dalous J, Mani S, El Ghouzzi V, Heijnen C, … Gressens P (2011). Stem cell therapy for neonatal brain injury: perspectives and challenges. Ann Neurol, 70(5), 698–712. doi:10.1002/ana.22518 [PubMed: 22162055]

Tremblay E, Roisin MP, Represa A, Charriautmarlangue C, & Benari Y (1988). TRANSIENT INCREASED DENSITY OF NMDA BINDING-SITES IN THE DEVELOPING RAT HIPPOCAMPUS, Brain Research, 461(2), 393–396. doi:10.1016/0006-8993(88)90275-2 [PubMed: 2902905]

Tsai CE, Daoed MJ, Lane RH, Hansen TWR, Gruetzmacher EM, & Watchko JF (2002). P-glycoprotein expression in mouse brain increases with maturation. Biology of the Neonate, 81(1), 58–64. doi:10.1159/000047185 [PubMed: 11803178]

van der Kooij MA, Groenendaal F, Kavalaars A, Heijnen CJ, & van Bel F (2008). Neuroprotective properties and mechanisms of erythropoietin in vivo and in vivo experimental models for hypoxia/ischemia. Brain Research Reviews, 59(1), 22–33. doi:10.1016/j.brainresrev.2008.04.007 [PubMed: 18514916]
van Vliet EA, Araujo S.d. C., Redeker S, van Schaik R, Aronica E, & Gorter JA (2007). Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain, 130, 521–534. doi:10.1093/brainawl318 [PubMed: 17124188]

Vannucci RC, & Vannucci SJ (2000). Glucose metabolism in the developing brain. Seminars in Perinatology, 24(2), 107–115. doi:10.1053/sp.2000.6361 [PubMed: 10805166]

Virgintino D, Errede M, Robertson D, Capobianco C, Girolamo F, Vimercati A, … Roncali L (2004). Immunolocalization of tight junction proteins in the adult and developing human brain. Histochemistry and Cell Biology, 122(1), 51–59. doi:10.1007/s00418-004-0665-1 [PubMed: 15221411]

Virgintino D, Girolamo F, Errede M, Capobianco C, Robertson D, Stallcup WB, … Roncali L (2007). An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis, 10(1), 35–45. [PubMed: 17225955]

Virgintino D, Girolamo F, Rizzi M, Ahmedli N, Sadowska GB, Stopa EG, … Stonestreet BS (2014). Ischemia/Reperfusion-Induced Neovascularization in the Cerebral Cortex of the Ovine Fetus. Journal of Neuropathology and Experimental Neurology, 73(6), 495–506. [PubMed: 24806298]

Virgintino D, Robertson D, Benagiano V, Errede M, Bertossi M, Ambrosi G, & Roncali L (2000). Immunogold cytochemistry of the blood-brain barrier glucose transporter GLUT1 and endogenous albumin in the developing human brain. Developmental Brain Research, 123(1), 95–101. doi:10.1016/s0165-3806(00)00086-9 [PubMed: 11020555]

Visse R, & Nagase H (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res, 92(8), 827–839. doi:10.1161/01.res.0000070112.80711.3d [PubMed: 12730128]

Wang HW, Wang XM, & Guo QY (2012). The correlation between DTI parameters and levels of AQP-4 in the early phases of cerebral edema after hypoxic-ischemic/reperfusion injury in piglets. Pediatric Radiology, 42(8), 992–999. doi:10.1007/s00247-012-2373-7 [PubMed: 22453895]

Wang L, Chopp M, Gregg SR, Zhang RL, Teng H, Jiang A, … Zhang ZG (2008). Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. Journal of Cerebral Blood Flow and Metabolism, 28(7), 1361–1368. doi:10.1038/jcbfm.2008.32 [PubMed: 18414495]

Wang RL, Wu XN, Liang J, Qi ZF, Liu XR, Min LQ, … Zhao HP (2015). Intra-artery infusion of recombinant human erythropoietin reduces blood-brain barrier disruption in rats following cerebral ischemia and reperfusion. International Journal of Neuroscience, 125(9), 693–702. doi:10.3109/01650218.2014.966354 [PubMed: 25226558]

Wu CC, Chen YC, Chang YC, Wang LW, Lin YC, Chiang YL, … Huang CC (2013). Human Umbilical Vein Endothelial Cells Protect Against Hypoxic-Ischemic Damage in Neonatal Brain via Stromal Cell-derived Factor 1/C-X-C Chemokine Receptor Type 4. Stroke, 44(5), 1402+. doi:10.1161/strokeaha.111.000719 [PubMed: 23449265]

Yan FF, Zhang MM, Meng Y, Li HJ, Yu L, Fu XJ, … Jiang C (2016). Erythropoietin improves hypoxic-ischemic encephalopathy in neonatal rats after short-term anoxia by enhancing angiogenesis. Brain Research, 1651, 104–113. doi:10.1016/j.brainres.2016.09.024 [PubMed: 27659964]

Yang C, Hawkins KE, Dore S, & Candelario-Jalil E Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. American Journal of Physiology-Cell Physiology, 0(0), null. doi:10.1152/ajpcell.00136.2018

Yu Y, Yan Y, Luo Z, Luo P, Xiao N, Sun X, & Cheng L (2018). Effects of human umbilical cord blood CD34(+) cell transplantation in neonatal hypoxic-ischemia rat model. Brain Dev. doi:10.1016/j.braindev.2018.08.007

Zhang JY, Sadowska GB, Chen XD, Park SY, Kim JE, Bodge CA, … Stonestreet BS (2015). Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. Faseb Journal, 29(5), 1739–1753. doi:10.1096/fj.14-258822 [PubMed: 25609424]

Zhang WT, Zhang H, Mu HF, Zhu W, Jiang XY, Hu XM, … Gao YQ (2016). Omega-3 polyunsaturated fatty acids mitigate blood-brain barrier disruption after hypoxic-ischemic brain injury. Neurobiology of Disease, 91, 37–46. doi:10.1016/j.nbd.2016.02.020 [PubMed: 26921472]
Zhao J, Mu H, Liu L, Jiang X, Wu D, Shi Y, … Ji X. (2018). Transient selective brain cooling confers neurovascular and functional protection from acute to chronic stages of ischemia/reperfusion brain injury. J Cereb Blood Flow Metab, 271678x18808174. doi:10.1177/0271678x18808174

Zhu LH, Bai X, Wang SY, Hu Y, Wang T, Qian LJ, & Jiang L (2014). Recombinant Human Erythropoietin Augments Angiogenic Responses in a Neonatal Rat Model of Cerebral Unilateral Hypoxia-Ischemia. Neonatology, 106(2), 143–148. doi:10.1159/000362262 [PubMed: 24969821]

Zlokovic BV (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 57(2), 178–201. doi:10.1016/j.neuron.2008.01.003 [PubMed: 18215617]
SIGNIFICANCE

Many brain related injuries can be attributed hypoxia-ischemic events at birth, which result in neurodevelopmental disabilities and place a lifelong burden on parents and society. This event in the developing and immature brain can cause significant mortality and result in long-term neurological abnormalities. Alterations in the components of the neurovasculature represent key contributors to hypoxic-ischemic related brain injury but still are not fully characterized in the neonatal brain. In addition, they also potentially represent promising pharmacological targets. In this review, we summarize the literature that has reported modifications in the neurovascular unit and potential beneficial drug candidates.
Figure 1: A summary of the neurovascular unit cellular responses after hypoxia ischemia in the neonatal brain
Table 1:
Summary of studies on the BBB permeability after neonatal HI brain injury

| REFERENCES | ANIMAL MODEL | INDICATOR OF INCREASE BBB PERMEABILITY |
|------------|--------------|----------------------------------------|
| **Rodent models** | | |
| Svedin, Hagberg, Savman, Zhu, & Mallard, 2007 | Mice HI model P9, 50 or 60 min of 10 % O<sub>2</sub> hypoxia | Extravagation of IgG up to 24 h after HI |
| W. Q. Chen, Jadhav, Tang, & Zhang, 2008 | Rat HI model P7, 2 h of 8 % O<sub>2</sub> hypoxia | Extravagation of IgG 24 h after HI |
| Ferrari, Nesic, & Perez-Polo, 2010 | Rat HI model P7, 90 min of 8 % O<sub>2</sub> hypoxia | Increases permeability to fluorescein from 24 h after HI to 7 days, normalization after 21 days |
| Tu et al., 2011 | Rat HI model P7, 2 h of 8 % O<sub>2</sub> hypoxia | Extravagation of IgG 24 h after HI |
| Tu, Lu, Huang, Ho, & Chou, 2012 | Rat HI model P7, LPS-sensitized, 80 min of 10 % O<sub>2</sub> hypoxia | Increases permeability to fluorescein 24 h after HI |
| D. Yang et al., 2013 | Mouse HI model P9, 50 min of 10 % O<sub>2</sub> hypoxia | Increases permeability to sucrose, peak at 6 h after HI and normalization in 3 days |
| Min et al., 2015 | Rat HI model P7; 2.5 h of 8 % O<sub>2</sub> hypoxia | Extravagation of IgG 24 h after HI |
| W. T. Zhang et al., 2016 | Rat HI model P7; 2.5 h of 8 % O<sub>2</sub> hypoxia | Extravagation of cadaverine 4 h after HI and 3kD and 40kD dextrans 24 and 48 h after HI Extravagation of IgG 48 h after HI |
| Ma et al., 2017 | Rat HI model P7, 90 min of 8 % O<sub>2</sub> hypoxia | Extravagation of IgG 48 h after HI |
| **Sheep model** | | |
| Sadowska et al., 2012 | 30 min bilateral carotid occlusion in the fetal sheep (125-129 days of gestation) | Increases permeability to amino-isobutyric acid up to 48 h of reperfusion and with a peak at 4 h |
| Yawno et al., 2012 | 10 min umbilical cord occlusion in the fetal sheep (130 days of gestation) | Extravagation of albumin after 48 h of reperfusion |
| Baburamani, Castillo-Melendez, & Walker, 2013 | 10 min umbilical cord occlusion in the fetal sheep (130 days of gestation) | Extravagation of albumin after 24 h and 48 h of reperfusion |
| Castillo-Melendez et al., 2015 | Single uterine artery ligation (105 days of gestation) | Extravagation of albumin 24 h after natural birth |